Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on commercializing products for the hospital, respiratory and related specialty markets. The Company's promoted products include CUROSURF, ZYFLO CR, FACTIVE and SPECTRACEF. On December 30, 2011, the Company acquired Cardiokine, Inc., a specialty pharmaceutical company, focused on developing hospital products for cardiovascular indications. In March 2012, it acquired the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets. In June 2012, the Company acquired EKR Therapeutics, Inc. In February 2014, Chiesi Farmaceutici S.p.A acquired Cornerstone Therapeutics Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:CRTX
Previous Symbol
CUSIP21924P10
Phone+1-919-6786611
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
Chiesi USA (NASDAQ:CRTX) Frequently Asked Questions
What is Chiesi USA's stock symbol?
Chiesi USA trades on the NASDAQ under the ticker symbol "CRTX."
Has Chiesi USA been receiving favorable news coverage?
Media headlines about CRTX stock have been trending very positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chiesi USA earned a media sentiment score of 3.9 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are Chiesi USA's key executives?
Chiesi USA's management team includes the folowing people:
- Kenneth R. McBean, President (Age 48)
- Craig Alexander Collard, Chief Executive Officer
- Alastair S. McEwan, Chief Financial Officer, Treasurer, Secretary (Age 62)
- Andreas Maetzel, Vice President - Clinical and Regulatory (Age 50)
- Alan T. Roberts, Vice President - Scientific Affairs (Age 47)
- Joshua B. Franklin, Vice President - Strategy and Business Development (Age 44)
- Ugo Di Francesco, Director
How do I buy shares of Chiesi USA?
Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chiesi USA's official website?
How can I contact Chiesi USA?
Chiesi USA's mailing address is 1255 Crescent Grn Ste 250, CARY, NC 27518-8128, United States. The specialty pharmaceutical company can be reached via phone at +1-919-6786611.
MarketBeat Community Rating for Chiesi USA (NASDAQ CRTX)
MarketBeat's community ratings are surveys of what our community members think about Chiesi USA and other stocks. Vote "Outperform" if you believe CRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
